Key Highlights

  • Third-quarter 2026 loss from operations was USD 4.7 million, against USD 7.7 million.
  • The company completed its Prana Therapies Acquisition on October 23, 2026.
  • A concurrent private Placement produced approximately USD 120 million in gross proceeds.
  • Phase 2 studies of PRA-216 began in asthma, atopic dermatitis and COPD.

Bolt Biotherapeutics (NASDAQ:BOLT) reported a third-quarter 2026 loss from operations of USD 4.7 million, against USD 7.7 million in the same quarter of 2025. The Redwood City, California-based clinical-stage company said it completed its acquisition of Prana Therapies in October and closed a concurrent private placement, making Prana's pipeline its primary development focus.

Quarterly Results

Total collaboration Revenue was zero for the quarter ended September 30, 2026, against USD 2.2 million a year earlier. The company states revenue in the comparative periods was generated from services performed under its Research and Development collaborations.

Research and development expenses were USD 2.2 million, against USD 6.5 million. The company attributes the decrease mainly to a research and development tax incentive, lower salary and related expenses following its restructuring, and lower overall research and development activities. General and administrative expenses were USD 2.5 million, against USD 3.3 million, which it attributes mainly to lower salary and related expenses following its restructuring and lower personnel expenses.

Prana Acquisition and Private Placement

Bolt acquired Prana Therapies on October 23, 2026 in a stock-for-stock reverse merger, through the issuance of 430,746 shares of common stock and 16,360.929 shares of Series D non-voting preferred stock, each convertible into 1,000 shares of common stock. The company said it plans to call and hold stockholder meetings as soon as practicable to approve the conversion of the Series D preferred stock into common stock and other matters specified in the merger agreement. It stated the disclosures required by ASC 805 are due no later than January 8, 2027.

Concurrent with the acquisition, the company sold and issued 13,995.311 shares of Series D preferred stock and accompanying warrants for aggregate gross proceeds of USD 120.0 million, not including any cash proceeds from exercise of the warrants, before placement agent fees and other offering expenses. Following the transaction, subject to stockholder approval of the conversion, the company reports approximately 34.2 million shares of common stock outstanding on an as-converted basis, before giving effect to exercise of the PIPE warrants.

Sheila Gujrathi, M.D., co-founder and former Chief Executive Officer of Prana, was appointed Chief Strategy Officer of Bolt and joined its board of directors. The company also reported that the Chesapeake Master Lease was terminated, with an effective lease expiration date of January 1, 2027.

PRA-216 and Pipeline

The company's lead program, PRA-216, is an IL-4Rα/TSLP bispecific antibody with extended half-life, now in Phase 2 development in asthma, chronic obstructive pulmonary disease and atopic dermatitis, with a fourth study planned in eosinophilic esophagitis. Gujrathi said patient proof-of-concept data across all four studies are projected to begin in the second quarter of 2027.

The company states recently disclosed Phase 1 data provided first clinical validation of PRA-216 and of its INSPIRE multispecific antibody platform, with the potential for at-home maintenance dosing every 8 to 12 weeks. It states a second wholly owned INSPIRE program is projected to enter the clinic and generate initial clinical data in the second half of 2027. Its pipeline also includes BDC-4182, a claudin 18.2-targeting Boltbody ISAC.

The company states the approximately USD 120 million private placement is projected to fund operations into 2028 and through multiple clinical and preclinical milestones. Chief Executive Officer Willie Quinn described the Prana acquisition as an important transformation for the company and said he believes it is well positioned to execute against upcoming milestones.